Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07597018 | A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity | PHASE1 | NOT YET_RECRUITING | 234 | — | — | May 18, 2026 | May 28, 2027 | May 19, 2026 | 1 | Germany |
Measured in hour nanomoles per litre (h\*nmol/L)
Measured in nanomoles per litre (nmol/L).
| Arm | Type | Description |
|---|---|---|
| Cagrilintide B and Placebo Semaglutide I | EXPERIMENTAL | Participants will receive Cagrilintide B and Placebo semaglutide I subcutaneously once weekly for up to 17 weeks. |
| Cagrilintide D-Injection site 1 | EXPERIMENTAL | Participants will receive Cagrilintide D subcutaneously once weekly for up to 17 weeks. |
| Cagrilintide D-Injection site 2 | EXPERIMENTAL | Participants will receive Cagrilintide D subcutaneously once weekly for up to 17 weeks. |
| Cagrilintide D-Injection site 3 | EXPERIMENTAL | Participants will receive Cagrilintide D subcutaneously once weekly for up to 17 weeks. |
| Name | Type | Description |
|---|---|---|
| Cagrilintide D | DRUG | Cagrilintide D will be administered subcutaneously. |
| Cagrilintide B and placebo semaglutide I | DRUG | Cagrilintide B and placebo semaglutide I will be administered subcutaneously |
Inclusion Criteria: * Aged 18-64 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 27.0 and 34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator. * Consi...